Last update 17 Jun 2025

TFX05-01

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TFX05 01, TFX05-01, TFX0501
Target
17β-HSD5
Action
inhibitors
Mechanism
17β-HSD5 inhibitors(Aldo-keto-reductase family 1 member C3 inhibitors)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseHemic and Lymphatic Diseases+ [1]
Active Indication
Advanced Malignant Solid NeoplasmAdrenocortical CarcinomaHematologic Neoplasms
Inactive Indication-
Originator Organization
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
Active Organization
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with TFX05-01
CTR20220957
/ RecruitingPhase 1
评估TFX05-01治疗晚期实体瘤受试者的安全性、耐受性、药代动力学、疗效以及与 AKR1C3酶表达相关性的临床研究。
[Translation] A clinical study to evaluate the safety, tolerability, pharmacokinetics, efficacy and correlation with AKR1C3 enzyme expression of TFX05-01 in the treatment of subjects with advanced solid tumors.
NCT05434299
/ RecruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TFX05-01 in Participants With Advanced Malignancies
100 Clinical Results associated with TFX05-01
Login to view more data
100 Translational Medicine associated with TFX05-01
Login to view more data
100 Patents (Medical) associated with TFX05-01
Login to view more data
100 Deals associated with TFX05-01
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
China
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
05 Jun 2022
Adrenocortical CarcinomaIND Approval
China
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
17 Jun 2025
Hematologic NeoplasmsIND Approval
China
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
14 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free